| Title | In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis. | | Author(s) | King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN | | Institution | Mpex Pharmaceuticals, Inc., San Diego, CA 92121; Seattle Children's Hospital, Seattle, WA 98105. | | Source | Antimicrob Agents Chemother 2009 Oct 5. | | Abstract | Inhalational administration of antibiotics can provide high concentrations locally in the lungs of cystic fibrosis patients and, thus, be useful in the treatment of chronic bacterial infections. This study evaluated the in vitro activity of levofloxacin, ciprofloxacin, tobramycin, amikacin and aztreonam against clinical isolates of Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and Staphylococcus aureus from cystic fibrosis patients. Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC90s ranging between 8 and 32 mug/ml. Levofloxacin was more potent against P. aeruginosa biofilms compared to the aminoglycosides or aztreonam. Timed-kill assays using drug concentrations achievable in sputum following aerosol administration showed levofloxacin had the most rapid rate of killing among mucoid and non-mucoid isolates of P. aeruginosa. In contrast to tobramycin, the bactericidal activity of levofloxacin was not affected by cystic fibrosis sputum. The results from this study show that high concentrations of levofloxacin readily achievable in the lung following aerosol delivery may be useful for management of pulmonary infections in patients with cystic fibrosis. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19805554 |
|
